REG - Venture Life Group - Trading Update & Board Changes

Venture LifeAnnouncement

01/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211201:nRSA1201Ua&default-theme=true

RNS Number : 1201U  Venture Life Group PLC  01 December 2021

1 December 2021

 

VENTURE LIFE GROUP PLC

("Venture Life", "Group" or the "Company")

 Trading Update & Board Changes

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, provides the following
update on trading and details of Board changes.

Trading update

Some of the themes that were referenced in the Company's Interim Results,
announced on 23 September 2021, have continued. The integration of BBI
Healthcare, the Company's largest ever acquisition, remains on track and the
Directors are pleased with the progress that has been made. The Helsinn
Integrative Care Portfolio, acquired in August this year, has also performed
in line with management's expectations and is further evidence of the
Company's skill in identifying and executing acquisitions well.

More specifically, through BBI Healthcare brands, evaluation is underway at
both Savers and Co-op on Balance Activ.  Also, given the success that Balance
Active has had on the Amazon platform in the UK, plans are underway to launch
the brand in Germany on Amazon, which is expected to take place in Q1 2022.

In the Interim Results, reference was made to some of the challenges that the
Group had been experiencing. These challenges persist; the ongoing impact of
COVID continues to affect confidence across many markets, with some customers
choosing to reduce inventory, rather than place new orders, and also to delay
orders at short notice. The industry continues to experience increased input
prices, not all of which can be passed on to customers immediately, along with
supply shortages for some components, and the well publicised issues with
truck availability / pricing have created additional uncertainty surrounding
logistics. The Company's Chinese partner has continued to disappoint against
expected levels of sales and, as a result, the Company is exploring
alternative opportunities to ensure that sales in China are maximised in 2022
and beyond.

The Company continues to await the publication of the peer-reviewed in vivo
study carried out by Cardiff University, which was completed in April this
year. Whilst the Board is disappointed that this has taken longer than
expected to publish, and does acknowledge that the timing is outside the
control of Cardiff University, it is hopeful the final publication will be
available soon.  Further, the Company notes the recent announcement made by
Salisbury Hospital regarding specific mouth care guidance for patients with
Covid-19.  As well as regular toothbrushing, the guidance also suggests that
both Dentyl Dual Action and Dentyl Fresh Protect should be used.  The Company
understands this guidance was based on research conducted by Doctors at
Salisbury Hospital, as well as the in-vitro (lab based) results widely
published by Cardiff University in November 2020.

 

In summary, the Directors see many reasons to be optimistic and are pleased
with how the Company is positioned, including its ability to react quickly to
address things that are within its control. The Company is profitable, cash
generative, with a healthy cash balance, and has a Revolving Credit Facility
as a source of non-dilutive funding for selective earnings enhancing
acquisitions, which it continues to assess. The Board, therefore, is confident
that the Company is well placed to capitalise on opportunities that it
believes will arise as a result of the current market conditions.

The Board expects December to be an important month of trading for the Group
but confidence in predicting certain deliverables, particularly logistics,
remains lower than normal. Whilst the Company believes that turnover for the
year will be not less than £32 million (not less than £37 million on a
proforma basis, assuming the BBI Healthcare and Helsinn acquisitions had been
in place for the full year), the final outcome for 2021 will be determined by
how these volatile issues conclude.  Actions have been taken by the Board to
mitigate the impact of some of the external factors affecting the Company and,
with our products set to be launched in new outlets internationally next year
and with our order book ahead of where it was at the same time last year (on a
like for like basis), the Company continues to look to 2022 with confidence.

Board changes

The Company also announces that, after eight years as Chair of the Group, Dr
Lynn Drummond is retiring from the Board. A process is underway to identify a
suitable successor and we will update the market on this in due course. Lynn
will continue to Chair the Board until that new appointment is made.

Lynn joined the Board of VLG in the autumn of 2013, and has presided over the
Board through the flotation of the Group on AIM in 2014, and its growth
through both acquired and organic means since then. The Group is now an
established, growing and sustainably profitable consumer healthcare business,
with operations in four countries and over 200 partners selling its products
in over 90 countries. The Board of VLG would like to thank Lynn for everything
she has done to support the management team of the business through this
exciting period of growth for the Group.

In addition, the Company announces that Mr Andrew Waters, Chief Financial
Officer, is leaving the business to pursue other business interests. He will
remain with the business over the next six months in order to provide a smooth
transition to his successor. Andrew joined the business in May 2019 and has
supported the growth of the business in recent years, through three
acquisitions and obtaining the Revolving Credit Facility. The Board would like
to thank Andrew for his time at VLG.

The Company has appointed Mr Daniel Wells as Chief Financial Officer, and he
will be appointed as a director of VLG as soon as practicable, subject to the
approval of the Company's Nominated Adviser in accordance in the AIM Rules,
and a further announcement will be made in due course. Daniel joined the Group
in June 2021 as part of the acquisition of private equity backed BBI
Healthcare, where he worked for the last two years in the role of Finance
Director and played an integral part in the sale of the business. Prior to
this, he spent ten years at a FTSE 250 company, Mitie Group PLC, in a variety
of senior finance and commercial roles across the UK and Ireland, including as
Divisional Head of Finance and later as Strategic Account Director for a major
UK retail customer with revenues of over £50 million per annum. Daniel
started his career in the private healthcare sector as part of the Corporate
Finance team at Hazlewoods LLP in Cheltenham. He is a chartered accountant and
a member of the AAT.

 

Jerry Randall, CEO of Venture Life, commented:

"I would like to express my deepest thanks to Lynn, who, after 8 years as our
Chair, is stepping down, and is making way for a new Chair to join the
business.  With Lynn as Chair, since before IPO, we have grown the business
into a substantial and sustainably profitable international consumer
healthcare business. Lynn leaves the business with a firm foundation for
future growth and I wish Lynn the very best for her future beyond VLG.

Andrew joined us in 2019 and has been with us through a period of growth, and
through the tough COVID times, and I would also like to thank Andrew for his
hard work and dedication here at VLG, and wish him well in his future
endeavours.

I am delighted to welcome Daniel Wells as CFO to the business; Danny has made
a very positive contribution to the Group already, since he joined at the time
of the BBI Healthcare acquisition in June.

As we highlighted in September, and has been reported widely in the media,
trading conditions at this time are challenging for many businesses. More
pleasingly, we are beginning to see positive traction in passing some price
increases onto customers, although this will take 12 months to fully wash
through. Also, in the second half, we have had the strong impact of the higher
margin acquisitions made in the summer, with both acquisitions performing well
and in line with our expectations.

Despite the difficult trading conditions through COVID, the business will grow
revenues year on year from 2020 to 2021 and we expect this growth to continue
in 2022 before any new acquisitions. The challenging trading conditions mean
that we are now more cautious about the levels of growth that we expect in the
immediate future, but we are confident that our growing revenues will deliver
growing profitability. We know that our resilient business is well placed to
deal with the challenges of this COVID environment and is well placed to
perform strongly when more normalised trading conditions return."

 

This announcement contains price sensitive information.

 

For further information, please contact:

 

 Venture Life Group PLC                              +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Joint Broker)      +44 (0) 20 7397 8900
 Michael Johnson/Russell Kerr (Sales)

 Stephen Keys/Camilla Hume (Corporate Finance)

 Singer Capital markets (Joint Broker)               +44 (0) 20 7496 3000
 Jonathan Dighe (Sales)

 Shaun Dobson/Alaina Wong (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Active range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products are sold in
over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTWPGPCGUPGPGU